Lisinopril and Hydrochlorothiazide description, usages, side effects, indications, overdosage, supplying and lots more!

Menu
Search

Lisinopril and Hydrochlorothiazide

REMEDYREPACK INC.


FULL PRESCRIBING INFORMATION: CONTENTS*




FULL PRESCRIBING INFORMATION

BOXED WARNING

USE IN PREGNANCY


LISINOPRIL AND HYDROCHLOROTHIAZIDE DESCRIPTION



Lisinopril and Hydrochlorothiazide



Lisinopril and Hydrochlorothiazide





CLINICAL PHARMACOLOGY

Lisinopril-Hydrochlorothiazide





Lisinopril

Mechanism of Action:




Pharmacokinetics and Metabolism:






Pharmacodynamics:








Hydrochlorothiazide





INDICATIONS & USAGE






LISINOPRIL AND HYDROCHLOROTHIAZIDE CONTRAINDICATIONS



WARNINGS

General

Lisinopril

Anaphylactoid and Possibly Related Reactions:


Angioedema:



Anaphylactoid reactions during desensitization:


Anaphylactoid reactions during membrane exposure:


Hypotension and related effects





Neutropenia/Agranulocytosis:


Hepatic Failure:


Hydrochlorothiazide






Pregnancy

Lisinopril-Hydrochlorothiazide



Lisinopril

Fetal/Neonatal Morbidity and Mortality:








Hydrochlorothiazide


PRECAUTIONS

General

Lisinopril

Aortic Stenosis/Hypertrophic Cardiomyopathy:


Impaired Renal Function:





Hyperkalemia:


Cough:


Surgery/Anesthesia:


Hydrochlorothiazide














INFORMATION FOR PATIENTS

Information for Patients

Angioedema:


Symptomatic Hypotension:



Hyperkalemia:


Neutropenia:


Pregnancy:



DRUG INTERACTIONS

Lisinopril

Hypotension

Patients on Diuretic Therapy:


Non-Steroidal Anti-inflammatory Agents:



Other Agents:


Agents Increasing Serum Potassium:


Lithium:


Hydrochlorothiazide


Alcohol, barbiturates, or narcotics -


Antidiabetic drugs (oral agents and insulin) -


Other antihypertensive drugs -


Cholestyramine and colestipol resins -


Corticosteroids, ACTH -


Pressor amines (e.g., norepinephrine) -


Skeletal muscle relaxants, nondepolarizing (e.g., tubocurarine)-


Lithium-


Non-Steroidal Anti-inflammatory Drugs -


CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY

Carcinogenesis, Mutagenesis, Impairment of Fertility

Lisinopril and Hydrochlorothiazide


Lisinopril




Hydrochlorothiazide




PREGNANCY



NURSING MOTHERS



PEDIATRIC USE

Pediatric Use


LISINOPRIL AND HYDROCHLOROTHIAZIDE ADVERSE REACTIONS






Lisinopril-HydrochlorothiazidePlacebo(n=930)(n=207)IncidenceIncidence(discontinuation)





Clinical Laboratory Test Findings

Serum Electrolytes



Serum Uric Acid, Glucose, Magnesium, Cholesterol, Triglycerides and Calcium:


Hemoglobin and Hematocrit:


Liver Function Tests:



Lisinopril -


Miscellaneous:


Fetal/Neonatal Morbidity and Mortality


Hydrochlorothiazide -


OVERDOSAGE



Lisinopril



Hydrochlorothiazide


DOSAGE & ADMINISTRATION





Dose Titration Guided by Clinical Effect


Replacement Therapy


Use in Renal Impairment


Use in Elderly


HOW SUPPLIED
























INACTIVE INGREDIENT

INACTIVE INGREDIENTS:
dibasic calcium phosphate

magnesium stearate
mannitol
pregelatinized starch
red iron oxide
starch(corn)
yellow iron oxide

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL SECTION














Lisinopril and Hydrochlorothiazide

Lisinopril and Hydrochlorothiazide

Lisinopril and Hydrochlorothiazide

Lisinopril and Hydrochlorothiazide TABLET

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:49349-247(NDC:63304-538)
Route of Administration ORAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
LISINOPRIL LISINOPRIL ANHYDROUS 20 mg
HYDROCHLOROTHIAZIDE HYDROCHLOROTHIAZIDE 25 mg

Inactive Ingredients

Ingredient Name Strength
DIBASIC CALCIUM PHOSPHATE DIHYDRATE
MAGNESIUM STEARATE
mannitol
STARCH, CORN
FERRIC OXIDE YELLOW
ferric oxide red

Product Characteristics

Color Size Imprint Code Shape
brown 8 mm RX538 ROUND

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:49349-247-02 30 in 1 BLISTER PACK

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA076007 2011-03-28


PLEASE, BE CAREFUL!
Be sure to consult your doctor before taking any medication!
Copyright © 2014. drugs-library.com. All rights reserved. Information on drugs-library.com is provided for educational purposes only and is not to be used for medical advice, diagnosis or treatment.
Support info@drugs-library.com.